The European Medicines Agency has updated the Q&A document on how companies should go about identifying, redacting, anonymizing and submitting clinical trial documents ahead of the phased re-start of its landmark transparency policy in September.
The Q&As have been revised to clarify the scope of the Clinical Data Publication (CDP) policy, and address procedural changes...